Avalo reports Q1 net loss $19.6M, Phase 2 HS trial meets endpoints, $431M offering

Avalo Therapeutics, Inc.

2026-Q1 EPS reported -$0.98

Phase 2 LOTUS topline: HiSCR75 absolute improvement 42.2% (150mg) and 42.9% (300mg) vs placebo 25.6%; p=0.018 and 0.015.
Q1 2026 net loss $19.6M ($0.98 loss/share) vs $13.1M prior year, driven by higher R&D costs.
Cash $82.0M as of Mar 31, 2026; subsequent public offering raised gross $431.3M (net $405M), extending runway into 2029.
Milestone Buyout Option: paid $2.25M for option to replace $15M milestone with $5.125M payment upon Phase 3 start.
R&D expense $14.0M (+$4.9M YoY); G&A $6.9M (+$1.3M YoY).

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Avalo Therapeutics, Inc. reported first quarter 2026 results: net income Net loss was $19.6 million, EPS Basic and diluted net loss per share was $0.98.

Period: first quarter 2026
Net income: Net loss was $19.6 million
EPS: Basic and diluted net loss per share was $0.98
Result: reported results

Exact text from the filing

On May 13, 2026, Avalo Therapeutics, Inc. issued a press release announcing its financial results for the quarter ended March 31, 2026.

View on SEC.gov

168 earnings releases filed in the last 30 days. Browse all earnings releases →

Avalo Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001534120-26-000032

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.